Regeneron Pharmaceuticals, Inc.
REGN
$767.96
$19.252.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.92% | 72.08% | -11.88% | -31.55% | -6.40% |
| Total Depreciation and Amortization | 1.18% | 6.46% | 0.40% | 3.86% | 0.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -290.54% | -668.16% | -106.59% | 384.61% | 63.10% |
| Change in Net Operating Assets | 374.24% | -275.85% | 250.00% | -35.21% | 92.97% |
| Cash from Operations | 41.45% | 9.50% | -17.24% | -2.20% | 264.75% |
| Capital Expenditure | 8.04% | 4.49% | -14.88% | 17.49% | -34.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.31% | -199.79% | 56.10% | 268.93% | 15.14% |
| Cash from Investing | 63.17% | -268.96% | 84.68% | 161.04% | -3.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27.94% | -48.02% | -33.33% | -64.31% | -41.80% |
| Repurchase of Common Stock | 37.49% | -2.05% | 14.73% | -43.39% | 6.60% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 1.51% | 1.28% | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | 100.00% | -- |
| Cash from Financing | 36.37% | -3.58% | 4.08% | -79.10% | -32.61% |
| Foreign Exchange rate Adjustments | -200.00% | -33.33% | 185.71% | -187.50% | 366.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.18% | -278.38% | 26.57% | 470.81% | 112.27% |